# US 2018/0022833 A1 · Microspheres of Hydrolysed Starch with Endogenous, Charged Ligands

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2018/0022833 A1
- Document ID: US20180022833A1
- Status: Published application
- Kind: A1
- Application number: 15/620,996
- Filed: 2017-06-13
- Published: 2018-01-25
- Earliest claimed: 2009-12-04
- Inventors: Malin Malmsjö; Eddie Thordarson; Sten Peter Apell; Peter Fyhr
- Web page: https://patentgrep.com/patent/US20180022833A1

## CPC

- C08B 31/003: {Crosslinking of starch}
- A61K 9/1652: {Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin (homeopathic globules A61K9/1623)}
- A61K 31/718: Starch or degraded starch, e.g. amylose, amylopectin
- A61L 15/28: Polysaccharides or their derivatives {(A61L15/225 takes precedence)}
- A61L 24/08: Polysaccharides {(A61L24/043 takes precedence)}
- A61P 7/04: Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- C08B 31/04: of organic acids {, e.g. alkenyl-succinated starch}
- A61L 2400/04: Materials for stopping bleeding
- A61L 2430/36: for embolization or occlusion, e.g. vaso-occlusive compositions or devices
- Y10T 428/2982: Particulate matter [e.g., sphere, flake, etc.]
- C08B: POLYSACCHARIDES; DERIVATIVES THEREOF (polysaccharides containing less than six saccharide radicals attached to each other by glycosidic linkages C07H; fermentation or enzyme-using processes C12P19/00; sugar industry C13; production of cellulose D21)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y10T: TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION

## Abstract

The resent invention relates to biodegradable microspheres having a diameter of 1-2000 μm comprising cross-linked hydrolysed starch onto which at least one type of ligand has been coupled via a carboxylic ester bond. The ligand shall be an endogenous, charged molecule with a molecular mass of less than 1000 Da comprising at least one additional carboxylic acid function in addition to the one utilised for coupling the ligand to the micro-sphere and/or at least one amine function. On average 0.05-1.5 ligands are coupled to each glucose moiety in the hydrolysed starch.

## Claims

### Claim at position 1

-20. (canceled)

### Claim 21

A method for carrying out hemostasis comprising the step of administering an effective amount of a biodegradable microsphere having a diameter of 10 to 2000 μm comprising cross-linked hydrolysed starch onto which at least one type of ligand, selected from the group consisting of amino acids and nitrogen containing organic acids, has been coupled via a carboxylic ester bond formed between the carboxylic acid group of the ligand and a hydroxyl group of a glucose residue in the cross-linked hydrolysed starch, wherein said ligand is an endogenous, charged molecule with a molecular mass of less than 1000 Da comprising at least one additional amine function, said ligand being positively charged or zwitter ionic, and wherein on average 0.05 to 1.5 ligands have been coupled to each glucose moiety in the hydrolysed starch, to a mammal suffering from a bleeding wound, thereby carrying out hemostasis.

### Claim 22 (depends on 21)

A microsphere according to claim 21, wherein said ligand is positively charged.

### Claim 23 (depends on 22)

A microsphere according to claim 22, wherein the ligand has a physiologically active counter ion.

### Claim 24 (depends on 21)

The method according to claim 21, wherein the microsphere has a mean diameter of 10 to 200 μm.

### Claim 25 (depends on 24)

The method according to claim 24, wherein the ligand has a physiologically active counter ion, the counter ion being ellagic acid.

### Claim 26 (depends on 21)

The method according to claim 21, wherein the ligand is an amino acid selected from the group consisting of arginine, histidine, lysine, glycine, proline, alanine, isoleucine, leucine, phenylalanine, tryptophan, tyrosine, valine, serine, aspargine, glutamine, threonine, glutamic acid and aspartic acid; or a nitrogen containing organic acid selected from the group consisting of betaine, carnitine, creatine, methylglycine, and dimethylglycine.

### Claim 27 (depends on 26)

The method according to claim 26, wherein the ligand is an amino acid selected from the group consisting of arginine, histidine, lysine, glycine, proline, alanine, isoleucine, leucine, phenylalanine, tryptophan, tyrosine, valine, serine, aspargine, glutamine, threonine; or a nitrogen containing organic acid selected from the group consisting of betaine, carnitine, creatine, methylglycine, and dimethylglycine.

### Claim 28 (depends on 27)

The method according to claim 27, wherein the ligand is a nitrogen containing organic acid selected from the group consisting of betaine, carnitine, creatine, methylglycine, and dimethylglycine.

### Claim 29

A method for carrying out wound healing comprising administering an effective amount of a material comprising biodegradable microspheres having a diameter of 10 to 2000 μm comprising cross-linked hydrolysed starch onto which at least one type of ligand, selected from the group consisting of amino acids and nitrogen containing organic acids, has been coupled via a carboxylic ester bond formed between the carboxylic acid group of the ligand and a hydroxyl group of a glucose residue in the cross-linked hydrolysed starch, wherein said ligand is an endogenous, charged molecule with a molecular mass of less than 1000 Da comprising at least one additional amine function, said ligand being positively charged, wherein on average 0.05 to 1.5 ligands have been coupled to each glucose moiety in the hydrolysed starch, and wherein said microspheres forms a three-dimensional structure comprising voids between the microspheres, to a mammal suffering from a wound, thereby carrying out wound healing.

### Claim 30 (depends on 29)

The method according to claim 29, wherein each microsphere is part of a homogenous size fraction with maximum variation of the mean diameter of ±15%.

### Claim 31 (depends on 29)

The method according to claim 29, wherein the microspheres have a mean diameter of from 200 μm to 2000 μm.

### Claim 32 (depends on 29)

The method according to claim 29, wherein the ligand is hydrophobic.

### Claim 33 (depends on 32)

The method according to claim 32, wherein the ligand is an amino acid selected from the group consisting of alanine, isoleucine, leucine, phenylalanine, tryptophan, tyrosine, and valine.

### Claim 34 (depends on 29)

The method according to claim 29, wherein the ligand is an amino acid selected from the group consisting of arginine, histidine, lysine, glycine, proline, alanine, isoleucine, leucine, phenylalanine, tryptophan, tyrosine, valine, serine, aspargine, glutamine, threonine, glutamic acid and aspartic acid; or a nitrogen containing organic acid selected from the group consisting of betaine, carnitine, creatine, methylglycine, and dimethylglycine.

### Claim 35 (depends on 34)

The method according to claim 34, wherein the ligand is an amino acid selected from the group consisting of arginine, histidine, lysine, glycine, proline, alanine, isoleucine, leucine, phenylalanine, tryptophan, tyrosine, valine, serine, aspargine, glutamine, threonine; or a nitrogen containing organic acid selected from the group consisting of betaine, carnitine, creatine, methylglycine, and dimethylglycine.

### Claim 36 (depends on 35)

The method according to claim 35, wherein the ligand is a nitrogen containing organic acid selected from the group consisting of betaine, carnitine, creatine, methylglycine, and dimethylglycine.
